Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future.

Authors :: Sturkenboom MG
Akkerman OW
Bolhuis MS
de Lange WC
van der Werf TS
Alffenaar JW
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Apr; Vol. 59 (4), pp. 2474.
Publication Year :: 2015

Subjects :: Female
Humans
Male
Antitubercular Agents pharmacokinetics
Dietary Fats pharmacokinetics
Food-Drug Interactions
Isoniazid pharmacokinetics
Rifampin pharmacokinetics
Tuberculosis, Pulmonary drug therapy

Full Text Access

Tools